$百奥泰(SH688177)$ We received US FDA approvals for Tyzavan and Ustekinumab, important additions to our portfolio that reflect our ability to bring high-value products to market. These products will be supported by our specialty commercial team and are expected to launch later this year.

乌斯奴美国即将开售